文献速递临床生化

一步酶法β-羟丁酸血检在临床生化平台上的评估:以HILIC-MS/MS为非酶参考方法

Evaluation of an enzymatic one-step assay for Beta-Hydroxybutyrate blood testing on clinical chemistry platforms using HILIC-MS/MS as a non-enzymatic reference method.
PubMed 文献 · Clin Chim Acta · 2025-11-07

该研究评估了DiaSys β-Hydroxybutyrate 21 FS(BHB 21 FS)一步酶法检测血清β-羟丁酸的分析性能,并以HILIC-ESI-MS/MS为非酶参考方法。结果显示该法线性范围0.05至6.0-8.0 mmol/L,总精密度CV≤3.3%,与参考方法相关性高(r=0.998),干扰试验偏差≤10%。结论支持其作为常规酮症和酮症酸中毒评估的可靠一步法。

要点

  • BHB 21 FS在3 mmol/L临床临界值处平均CV为1.93%,总精密度CV≤3.3%。
  • 与HILIC-MS/MS参考方法相关性r=0.998,偏差4.0%。
  • 溶血、脂血、黄疸样本干扰偏差≤10%,校准稳定10-16周。

核心结论

  • DiaSys BHB 21 FS一步酶法检测β-羟丁酸具有稳健的分析性能,与酶法和质谱法高度一致,可用于常规酮症和酮症酸中毒评估。

研究设计与样本

  • 按CLSI指南在血清样本中评估BHB 21 FS一步酶法的线性、重复性和总精密度,并与两种商业两步法及HILIC-ESI-MS/MS非酶参考方法比对。

主要发现

  • BHB 21 FS线性测量范围为0.05至6.0-8.0 mmol/L,总精密度CV≤3.3%,在3 mmol/L临界值处平均CV为1.93%。
  • 与EKF BHB LiquiColor®在三种分析仪上相关性r=0.999、偏差≤1%;与DiaSys BHB FS相关性r=0.998、偏差5.0%;与HILIC-MS/MS参考方法相关性r=0.998、偏差4.0%。
  • 在高溶血、脂血或黄疸样本中干扰测试偏差≤10%;在主动冷却平台校准和 onboard 稳定性维持10-16周。

关键数值与推荐

  • 线性范围0.05至6.0-8.0 mmol/L。
  • 总精密度CV≤3.3%,3 mmol/L处平均CV为1.93%。
  • 与EKF BHB LiquiColor®偏差≤1%,与DiaSys BHB FS偏差5.0%,与HILIC-MS/MS偏差4.0%。
  • 溶血、脂血、黄疸样本偏差≤10%。
  • 主动冷却平台校准和 onboard 稳定性10-16周。

临床怎么用

  • 该一步酶法可用于临床生化平台常规检测β-羟丁酸,辅助酮症和糖尿病酮症酸中毒的评估与监测。
  • 在主动冷却平台上可维持校准和 onboard 稳定性10-16周,适合常规批量检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: β-Hydroxybutyrate (β-HB), the predominant circulating ketone body, serves as alternative energy source during periods of glucose deprivation. Accurate quantification of β-HB is essential for the clinical assessment and monitoring of ketosis and diabetic ketoacidosis (DKA). METHODS: We evaluated the analytical performance of the DiaSys β-Hydroxybutyrate 21 FS assay (BHB 21 FS), a one-step enzymatic assay based on β-hydroxybutyrate dehydrogenase-catalyzed oxidation of β-HB to generate NADH, which is photometrically measured at 340 nm. Performance characteristics, including linearity, repeatability, and total precision, were assessed in serum samples following CLSI guidelines. The BHB 21 FS assay was benchmarked against two commercial two-step assays and a non-enzymatic reference method (HILIC-ESI-MS/MS). RESULTS: The BHB 21 FS assay showed a linear measuring range from 0.05 up to 6.0-8.0 mmol/L and CLSI-compliant total precision (CV ≤3.3 %), notably at the clinically relevant 3 mmol/L cut-off (mean CV: 1.93 %). Method comparison demonstrated excellent correlation with EKF BHB LiquiColor® across three different analyzers (r = 0.999; bias ≤1 %), and high concordance with DiaSys BHB FS (r = 0.998; bias 5.0 %) and the HILIC-MS/MS reference method (r = 0.998; bias 4.0 %). Interference testing indicated robust performance even in highly hemolytic, lipemic, or icteric samples (≤10 % deviation). On platforms with active cooling compartments, calibration and onboard stability were maintained for 10-16 weeks. CONCLUSION: The DiaSys BHB 21 FS assay combines robust analytical performance and high concordance with both enzymatic and mass spectrometric methods. These features support its use as a reliable one-step assay for routine clinical assessment of ketosis and ketoacidosis.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Steinbach MK, Müller H, Reichard Y, et al. Evaluation of an enzymatic one-step assay for Beta-Hydroxybutyrate blood testing on clinical chemistry platforms using HILIC-MS/MS as a non-enzymatic reference method. Clin Chim Acta. 2025. PMID: 41207600. doi:10.1016/j.cca.2025.120703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。